Checkpoint inhibitor prolongs survival with certain head and neck cancers
Compared to the standard therapy, survival was significantly improved for participants with previously untreated recurrent or metastatic head and neck cancers.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
More News: Cancer | Cancer & Oncology | Head and Neck Cancer | Health | Science | Universities & Medical Training | Yale